US-based medical equipment firm Edwards Lifesciences has secured the European CE-Mark for the use of its self-expanding heart valve, Centera, in severe, symptomatic aortic stenosis patients who are at high risk of open-heart surgery.

Designed as a repositionable and retrievable device, Centera comes pre-attached to a 14-French, motorised delivery system.

The transcatheter aortic valve replacement (TAVR) option is intended to allow stable deployment and simplified approach.

Edwards Lifesciences transcatheter heart valves corporate vice-president Larry Wood said: “Edwards is committed to partnering with clinicians to offer differentiated, best-in-class technologies for transcatheter heart valve therapy.

“European certification of the Centera valve provides a meaningful treatment option for high-risk TAVR patients when their heart team recommends a self-expanding device.”

“The self-expanding valve was reported to have led to high survival rates of 99%, low rates of 2.5% disabling stroke, and 4.9% permanent pacemaker rate at 30 days.”

The European clearance is based on the data obtained from the multi-centre Centera-EU clinical trial performed in 203 high-risk patients at 23 sites across Europe, Australia, and New Zealand.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When treated through the transfemoral access route, the self-expanding valve was reported to have led to high survival rates of 99%, low rates of 2.5% disabling stroke, and 4.9% permanent pacemaker rate at 30 days.

In addition, there was a low rate (around 0.6%) of moderate and no incidents of severe paravalvular leak. All the subjects in the trial were followed for a period of five years.

Edwards Lifesciences consultant Didier Tchétché said: “With the Edwards Centera valve, European clinicians and their patients may now benefit from a self-expanding TAVR option that has demonstrated exceptional clinical safety and performance outcomes in the high surgical risk population.”